OMBYNCA Trademark

Trademark Overview


On Thursday, March 21, 2019, a trademark application was filed for OMBYNCA with the United States Patent and Trademark Office. The USPTO has given the OMBYNCA trademark a serial number of 88350569. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 14, 2022. This trademark is owned by Eli Lilly and Company. The OMBYNCA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use i...
ombynca

General Information


Serial Number88350569
Word MarkOMBYNCA
Filing DateThursday, March 21, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 14, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 11, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain
Translation of Words in MarkThe wording "OMBYNCA" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 8, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, March 14, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 14, 2022ABANDONMENT - NO USE STATEMENT FILED
Saturday, July 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 1, 2021SOU EXTENSION 4 GRANTED
Thursday, July 1, 2021SOU EXTENSION 4 FILED
Thursday, July 1, 2021SOU TEAS EXTENSION RECEIVED
Thursday, January 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 12, 2021SOU EXTENSION 3 GRANTED
Tuesday, January 12, 2021SOU EXTENSION 3 FILED
Tuesday, January 12, 2021SOU TEAS EXTENSION RECEIVED
Friday, August 7, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 6, 2020SOU EXTENSION 2 GRANTED
Friday, July 10, 2020SOU EXTENSION 2 FILED
Thursday, August 6, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, July 10, 2020SOU TEAS EXTENSION RECEIVED
Friday, January 17, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 15, 2020SOU EXTENSION 1 GRANTED
Wednesday, January 15, 2020SOU EXTENSION 1 FILED
Wednesday, January 15, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, August 6, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 11, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 11, 2019PUBLISHED FOR OPPOSITION
Wednesday, May 22, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 1, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 16, 2019ASSIGNED TO EXAMINER
Monday, April 8, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 25, 2019NEW APPLICATION ENTERED